JAK2


Also found in: Medical.
AcronymDefinition
JAK2Janus-Activated Kinase 2
JAK2Janus Family Kinase-2 (endocrinology)
JAK2Just Another Kinase 2 (now Janus-Activated Kinase 2; biochemistry)
References in periodicals archive ?
Analysis of the JAK2 V617F mutation: Granulocytes were separated from peripheral blood (10 ml) and genomic DNA was extracted using conventional gradient centrifugation technique.
Earlier, JAK2 was only thought to function on the inner surface of cells.
According to the terms of the agreement, Ipsogen grants ARUP, a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development, non-exclusive rights, for the US territory, to offer a complete range of assays for the molecular classification and the screening of Myeloproliferative Neoplasms (MPN), a group of leukaemia's caused by JAK2 gene variations that affects more than 100,000 people in the US.
"We are pleased with the advancement of our JAK2 inhibitor into a Phase 1/2 clinical trial in Australia as it exemplifies the expansion of our company's global development strategy," said Dr.
The team found that 16 of 81 samples from patients with Down syndrome had the JAK2 mutation.
Furthermore, mRNA expression of Leptin, LEPR, JAK2, STAT3, KISS1 and TRPC5 were detected in the adipose and hypothalamic tissue of pre-puberty and puberty onset goats, respectively, by Real-time PCR, which was aimed to see whether the changes of adipose affect the ability of leptin to activate signaling pathways and modulate the expression of hypothalamic genes involved in reproduction and metabolism.
PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer.
An ad-hoc analysis of pooled data from PERSIST-1 and PERSIST-2 evaluated results from patients with platelet counts of less than 50,000 per microliter and showed that 23% (n=104) of patients administered pacritinib had a ?35% spleen volume reduction (SVR), compared to 2% (n=48) (p=0.0007) given the best available therapy, which in the PERSIST-1 trial excluded JAK2 inhibitors and in the PERSIST-2 trial included the approved JAK2 inhibitor, ruxolitinib.
The most frequent mutation in BCR-ABL2 negative MPN, JAK2 exon 14 (V617F) mutations are observed in 95% of PV patients (77).
The National Comprehensive Cancer Network guidelines recommend testing for the JAK2, MPL, and CALR genes (1-3) as part of the diagnostic workup of patients being assessed for MDS or MPN, to provide both diagnostic and prognostic guidance in treating the patient.
Until 2005, genetic cause of these hematological diseases was not clear.In the year 2005, a single point mutation (JAK2V617F) in the cytoplasmic tyrosine kinase JAK2 gene was proposed by several researchers in most of patients with PV, ET and PMF.4,6,10 Jak 2 gene is situated on chromosome 9p.24
The specific SS, PRL receptor, JAK2, STAT5, DGAT1, as well as GAPDH primers (Table I) were designed and synthesized by Sangon Biotech (Shanghai, China).